Research on Radioimmunotherapy of Lung Cancer in Nude Mice Using Lung Cancer Monoclonal Antibody LC-1 Combined with 90Y

L. Zeng,D. Ge

DOI: https://doi.org/10.1200/jco.2004.22.14_suppl.9631

IF: 45.3

2004-01-01

Journal of Clinical Oncology

Abstract:9631 Research on Radioimmunotherapy of lung cancer in nude mice using lung cancer monoclonal antibody LC-1 combined with 90Y Abstract Background: to evaluate potential clinical roles of monoclonal antibody (MoAb)-based therapies in the treatment of lung cancer. Methods: Anti-lung cancer monoclonal anibody LC-l IgM was combined with 90Y to produce radioimmunological targeting drug. Human lung cancer tissue was inoculated subcutaneously in 35 nude mice. They were randomized into seven groups while the tumor is 5mm in diameter. The groups were divided by the dose of the drug injected to the tail vein of the mice: blank group,LC-1 IgM, 90Y50uCi, 50uCi, l50uCi, 300uCi and 400uCitherapy groups. The size of the tumor was measured weekly and the mice were killed in four weeks after treatment. The tumors were resected and weighed. Results: As compared to blank group, therapy groups' tumor growth was inhibited and the inhibition was dose and time dependent. The inhibition rates of 300uCi and 400uCi grIoups were significantly different(<0.05). Conclusions: The results indicated that the radioimmunological drug made from lung cancer monoclonal anibody LC-1IgM and 90Y can specifically localise in tumor tissue and ensure radioimmunological targeting therapy, so has underlying clinical value. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration National Natural Science Foundation of China